Symbiotec Pharmalab Limited IPO — Subscription & GMP
- Price band
- ₹938 – ₹988
- Lot size
- 15
- Issue size
- ₹1,296.74 Cr
- Bidding
- 24 Aug 2026 → 27 Aug 2026
- Allotment
- —
- Listing
- 01 Sept 2026
Listing outcome
Official exchange pricesGMP was out by 25.8 percentage points against the buyer — it implied +25.81% and the issue listed 0.00%. Counted in our running GMP accuracy record.
Schedule
- 24 Aug 2026IPO open date
- 27 Aug 2026IPO close date
- 28 Aug 2026Allotment date†
- 28 Aug 2026Funds unblock or debit†
- 01 Sept 2026Tentative listing date
† Derived from the close date using the T+3 working-day timeline. The exchanges publish the open and close dates; the rest are indicative until confirmed, and exchange holidays are not accounted for.
Fundamentals
The business, its valuation and returnsBusiness Model of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), Contract Development and Manufacturing Organization (CDMO) services, and complex injectables.
- Core Offerings: The company's operations are heavily centered around its API portfolio, which specifically focuses on corticosteroids and steroidal-hormone APIs. In addition to APIs, its CDMO business provides tailored development and manufacturing services for pharmaceutical, nutraceutical, and wellness companies. It is also actively developing complex injectable products, leveraging its in-house API production.
- Market Dominance & Global Reach: Symbiotec holds a leading global position, commanding a 38.2% global volume market share in corticosteroids and 23.8% in steroidal hormone APIs as of FY26. It captures dominant global volume shares for major molecules like Hydrocortisone (80.1%), Testosterone (76.4%), and Methylprednisolone (76%). Its B2B clientele is highly international, with over 67% of its revenue derived from overseas markets.
- Manufacturing Capabilities: A significant strength of the business is its backward-integrated manufacturing infrastructure. Operating out of Madhya Pradesh, India, the company boasts one of the largest industrial-scale fermentation capacities (700 KL), reducing its reliance on external suppliers for key raw intermediates. Its facilities maintain strict global regulatory compliance, holding approvals from the US FDA and EU-GMP.
- Revenue Generation: The company primarily generates its revenue through the high-volume, B2B sale of its specialized APIs to global pharmaceutical manufacturers, which accounted for approximately 96% of its revenue in FY26. This is supplemented by income from its growing CDMO services and the sale of formulated complex injectables.
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS | ₹19.10 | — |
| P/E ratio | 51.73× | — |
| NAV per share | ₹184.69 | — |
Promoter holding pre/post issue is in the offer document but we do not yet extract it. Left blank rather than estimated.
Read from the company’s offer document filed with SEBI. Figures are the latest reported financial year, as restated in that filing.
Figures are as reported and not independently audited, and are read 45 d ago.
Grey market premium
Unofficial · not from any exchangeSubscription status
Live from NSE · fetched 773 hr ago| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| 1Qualified Institutional Buyers(QIBs) | 37.40 L | 53.21 Cr | 142.28× |
| 1(a)Foreign Institutional Investors(FIIs) | — | 7.34 Cr | — |
| 1(b)Domestic Financial Institutions(Banks/ Financial Institutions(FIs)/ Insurance Companies) | — | 33.12 Cr | — |
| 1(c)Mutual funds | — | 2.65 Cr | — |
| 1(d)Others | — | 10.11 Cr | — |
| 2Non Institutional Investors | 28.05 L | 17.89 Cr | 63.80× |
| 2.1Non Institutional Investors(Bid amount of more than Ten Lakh Rupees) | 18.70 L | 13.94 Cr | 74.57× |
| 2.1(a)Corporates | — | 11.22 L | — |
| 2.1(b)Individuals(Other than RIIs) | — | 13.14 Cr | — |
| 2.2Non Institutional Investors(Bid amount of more than Two Lakh Rupees upto Ten Lakh Rupees) | 9.35 L | 3.95 Cr | 42.25× |
| 3Retail Individual Investors(RIIs) | 65.45 L | 5.41 Cr | 8.27× |
| 3(a)Cut Off | — | 4.56 Cr | — |
| 3(b)Price bids | — | 85.49 L | — |
| 4Employees | 35,377 | 3.09 L | 8.72× |
| 4(b)Price Bids | — | 64,035 | — |
| Total | 1.31 Cr | 76.55 Cr | 58.32× |
Source: NSE issue information · BSE public issue
Demand curve
Shares bid at each price point · BSE₹938 → ₹988 · peak 93.57 Cr shares bid
Anchor investors
From NSE's anchor allocation filingAnchor investors are institutions allotted shares one working day before public bidding opens, in exchange for a lock-in. Up to 60% of the QIB portion can go to them, which reduces the QIB shares left for everyone else — and their participation is widely read as a confidence signal.
Anchor allocation report (NSE)
This issue’s anchor letter was filed as a scanned image with no text layer, so the allocation table cannot be read without OCR. We link the filing rather than publish figures we cannot verify.
Equity split
Fresh equity vs offer for sale- Fresh equity
- ₹150.00 Cr 8.5%
- Offer for sale
- ₹1.61k Cr 91.5%
- Total issue size
- ₹1.76k Cr
Read from the issue size stated in NSE's filing.
Allotment status
You will need your PAN, application number or DP/client ID. These links go to the registrar and exchanges directly — UpcomingIPO never asks for those details.
Issue details
- Price band
- ₹938 – ₹988
- Lot size
- 15 shares
- Min. bid quantity
- 15
- Face value
- ₹2.00
- Tick size
- ₹1.00
- Shares offered
- 1.31 Cr
- Issue size
- ₹1296.74 Cr
- Max bid · QIB
- 1.31 Cr
- Max bid · NII
- 93.50 L
Timeline & process
- Bidding opens
- 24 Aug 2026
- Bidding closes
- 27 Aug 2026
- Bidding hours
- 10 AM TO 5 PM
- UPI mandate cutoff
- 27 AUGUST 2026 (up to 5 pm)
- Allotment
- —
- Listing
- 01 Sept 2026
Intermediaries
- Registrar
- MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)
- Sponsor bank
- KOTAK BANK
- Lead managers
- JM Financial Limited, Nomura Financial Advisory and Securities (India) Private Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited